Innovative Products Continued to Deliver and Perform ExcellentlyRevenue Recorded RMB26.20 BillionAdjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB2.59 Billion HONG KONG, Mar 29, 2024 – (ACN Newswire) – Sino Biopharmaceutical Limited (Sino Biopharm or the Company, together with its subsidiaries, the Group) (HKG:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023. During the year, the Group recorded revenue of approximately RMB26.20 billion, an increase of approxim…